Japan uptake of Simponi music to Mitsubishi Tanabe's ears
This article was originally published in Scrip
Simponi (golimumab) is so far living up to Mitsubishi Tanabe Pharma's (MTP) expectations in Japan, with sales of the monoclonal antibody for rheumatoid arthritis coming in slightly ahead of the firm's internal forecasts.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.